These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 28481241)

  • 1. Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
    Capper D; von Deimling A; Brandes AA; Carpentier AF; Kesari S; Sepulveda-Sanchez JM; Wheeler HR; Chinot O; Cher L; Steinbach JP; Specenier P; Rodon J; Cleverly A; Smith C; Gueorguieva I; Miles C; Guba SC; Desaiah D; Estrem ST; Lahn MM; Wick W
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28481241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
    Brandes AA; Carpentier AF; Kesari S; Sepulveda-Sanchez JM; Wheeler HR; Chinot O; Cher L; Steinbach JP; Capper D; Specenier P; Rodon J; Cleverly A; Smith C; Gueorguieva I; Miles C; Guba SC; Desaiah D; Lahn MM; Wick W
    Neuro Oncol; 2016 Aug; 18(8):1146-56. PubMed ID: 26902851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
    Herbertz S; Sawyer JS; Stauber AJ; Gueorguieva I; Driscoll KE; Estrem ST; Cleverly AL; Desaiah D; Guba SC; Benhadji KA; Slapak CA; Lahn MM
    Drug Des Devel Ther; 2015; 9():4479-99. PubMed ID: 26309397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
    Rodón J; Carducci M; Sepulveda-Sánchez JM; Azaro A; Calvo E; Seoane J; Braña I; Sicart E; Gueorguieva I; Cleverly A; Pillay NS; Desaiah D; Estrem ST; Paz-Ares L; Holdhoff M; Blakeley J; Lahn MM; Baselga J
    Invest New Drugs; 2015 Apr; 33(2):357-70. PubMed ID: 25529192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
    Wick A; Desjardins A; Suarez C; Forsyth P; Gueorguieva I; Burkholder T; Cleverly AL; Estrem ST; Wang S; Lahn MM; Guba SC; Capper D; Rodon J
    Invest New Drugs; 2020 Oct; 38(5):1570-1579. PubMed ID: 32140889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats.
    Liu X; Yu M; Chen Y; Zhang J
    Braz J Med Biol Res; 2016 Aug; 49(9):e5388. PubMed ID: 27509307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study.
    Kovacs RJ; Maldonado G; Azaro A; Fernández MS; Romero FL; Sepulveda-Sánchez JM; Corretti M; Carducci M; Dolan M; Gueorguieva I; Cleverly AL; Pillay NS; Baselga J; Lahn MM
    Cardiovasc Toxicol; 2015 Oct; 15(4):309-23. PubMed ID: 25488804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts.
    Maier A; Peille AL; Vuaroqueaux V; Lahn M
    Cell Oncol (Dordr); 2015 Apr; 38(2):131-44. PubMed ID: 25573078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.
    Beije N; Kraan J; Taal W; van der Holt B; Oosterkamp HM; Walenkamp AM; Beerepoot L; Hanse M; van Linde ME; Otten A; Vernhout RM; de Vos FY; Gratama JW; Sleijfer S; van den Bent MJ
    Br J Cancer; 2015 Jul; 113(2):226-31. PubMed ID: 26042933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.
    Melisi D; Garcia-Carbonero R; Macarulla T; Pezet D; Deplanque G; Fuchs M; Trojan J; Oettle H; Kozloff M; Cleverly A; Smith C; Estrem ST; Gueorguieva I; Lahn MMF; Blunt A; Benhadji KA; Tabernero J
    Br J Cancer; 2018 Nov; 119(10):1208-1214. PubMed ID: 30318515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma.
    Duerinck J; Du Four S; Bouttens F; Andre C; Verschaeve V; Van Fraeyenhove F; Chaskis C; D'Haene N; Le Mercier M; Rogiers A; Michotte A; Salmon I; Neyns B
    J Neurooncol; 2018 Jan; 136(1):115-125. PubMed ID: 28988341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
    Kelley RK; Gane E; Assenat E; Siebler J; Galle PR; Merle P; Hourmand IO; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Faivre S; Benhadji KA; Giannelli G
    Clin Transl Gastroenterol; 2019 Jul; 10(7):e00056. PubMed ID: 31295152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
    Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
    Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
    Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
    J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma.
    Harding JJ; Do RK; Yaqubie A; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Benhadji KA; Kelley RK; Abou-Alfa GK
    Cancer Med; 2021 May; 10(9):3059-3067. PubMed ID: 33811482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lomustine and Bevacizumab in Progressive Glioblastoma.
    Wick W; Gorlia T; Bendszus M; Taphoorn M; Sahm F; Harting I; Brandes AA; Taal W; Domont J; Idbaih A; Campone M; Clement PM; Stupp R; Fabbro M; Le Rhun E; Dubois F; Weller M; von Deimling A; Golfinopoulos V; Bromberg JC; Platten M; Klein M; van den Bent MJ
    N Engl J Med; 2017 Nov; 377(20):1954-1963. PubMed ID: 29141164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.
    Fujiwara Y; Nokihara H; Yamada Y; Yamamoto N; Sunami K; Utsumi H; Asou H; TakahashI O; Ogasawara K; Gueorguieva I; Tamura T
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1143-52. PubMed ID: 26526984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.
    Serova M; Tijeras-Raballand A; Dos Santos C; Albuquerque M; Paradis V; Neuzillet C; Benhadji KA; Raymond E; Faivre S; de Gramont A
    Oncotarget; 2015 Aug; 6(25):21614-27. PubMed ID: 26057634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galunisertib modifies the liver fibrotic composition in the Abcb4Ko mouse model.
    Hammad S; Cavalcanti E; Werle J; Caruso ML; Dropmann A; Ignazzi A; Ebert MP; Dooley S; Giannelli G
    Arch Toxicol; 2018 Jul; 92(7):2297-2309. PubMed ID: 29808285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
    Batchelor TT; Mulholland P; Neyns B; Nabors LB; Campone M; Wick A; Mason W; Mikkelsen T; Phuphanich S; Ashby LS; Degroot J; Gattamaneni R; Cher L; Rosenthal M; Payer F; Jürgensmeier JM; Jain RK; Sorensen AG; Xu J; Liu Q; van den Bent M
    J Clin Oncol; 2013 Sep; 31(26):3212-8. PubMed ID: 23940216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.